SCHEDULE: Intracoastal Capital Reports 9.99% Stake in Silo Pharma

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 125,261 shares, representing 9.99% of Silo Pharma, Inc.'s common stock.

Summary

• Reporting Persons, including Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, have filed a Schedule 13G.
• As of June 30, 2026, the Reporting Persons collectively beneficially own 125,261 shares of Silo Pharma, Inc. common stock.
• This ownership stake represents 9.99% of the company's outstanding common stock.
• The reported shares are primarily derived from the exercise of warrants held by Intracoastal Capital LLC.
• The filing details specific warrants (Intracoastal Warrant 1, 2, 3, 4, and 5) and their associated blocker provisions which limit the number of shares that can be beneficially owned.
• Without these blocker provisions, the Reporting Persons could potentially beneficially own 222,995 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily due to the reporting of a significant ownership stake, but lacking substantial forward-looking financial data.

Positives

• Significant ownership stake of 9.99% reported by Intracoastal Capital LLC and associated individuals.
• Clarity on the source of ownership through specific warrant details.
• Disclosure of potential ownership (222,995 shares) if blocker provisions were not in effect, indicating substantial underlying interest.

Negatives

• The filing is a Schedule 13G, which is an informational filing and does not inherently contain operational or financial performance data.
• Bloker provisions in warrants limit the immediate exercisable ownership to 9.99%, preventing a higher stake.
• The filing does not provide details on the company's current financial health or future performance.

Risks

• The blocker provisions in the warrants (Intracoastal Warrant 3, 4, and 5) limit the ability to increase ownership beyond certain thresholds (9.99% and 4.99%), potentially restricting future strategic moves.
• The reliance on warrant exercises for ownership means the stake is contingent on the company's stock performance and the decision to exercise.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on ownership stakes.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their holdings. This filing indicates a substantial investment by Intracoastal Capital LLC in Silo Pharma, Inc., suggesting a belief in the company's potential by a key financial entity.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by Intracoastal Capital may be viewed positively, potentially indicating confidence in the company's future prospects. However, the limitations imposed by warrant blocker provisions might temper immediate positive sentiment.
• Management: The increased scrutiny from a 9.99% shareholder may influence strategic decisions and corporate governance practices.
• Creditors: No direct impact is indicated in this filing.

Next Steps

• The Reporting Persons will continue to monitor their beneficial ownership in Silo Pharma, Inc.

Key Dates

Recommendation

The filing indicates a significant ownership stake, which can be a positive signal. However, it's an informational filing (Schedule 13G) and lacks detailed financial performance or forward-looking guidance. The presence of warrant blocker provisions also limits immediate upside potential. Therefore, a 'hold' recommendation is appropriate pending further operational and financial disclosures from Silo Pharma, Inc.

Keywords

Silo Pharma, Intracoastal Capital, Schedule 13G, Beneficial Ownership, Warrants, Ownership Stake, SEC Filing, Mitchell P. Kopin